Furthers Mission to Address Unmet Medical Needs Across the Globe
TAMPA, Florida, Dec. 6, 2016 /PRNewswire/ -- Teewinot Life Sciences Corporation (Teewinot), a global leader in the use of biosynthetic processes for the production of kilogram quantities of pharmaceutical grade cannabinoids, announced today that its Irish subsidiary, Full Spectrum Laboratories, Ltd. (FSL), was granted a U.S. patent, U.S. Patent No. 9,512,391 (the '391 patent), covering an apparatus for biosynthetic production of the cannabinoids THCA, CBDA and CBCA. The '391 patent claims an apparatus for a biosynthetic production of cannabinoids THCA, CBDA and CBCA using THCA synthase and CBDA synthase. The apparatus is designed to manufacture kilogram quantities of pharmaceutically pure cannabinoids having the same chemical structure as the cannabinoids extracted from the Cannabis plant.
Teewinot's Executive Vice President and co-inventor of the '391 patent, Dr. Richard Peet, stated that "Teewinot's revolutionary and proprietary technology makes possible the production of a diverse range of cannabinoids in large quantities. For example, Teewinot is the first company to be able to manufacture kilogram quantities of pharmaceutically pure CBCA. Teewinot's Irish subsidiary, FSL, owns a rapidly expanding patent portfolio covering processes for manufacture of cannabinoids, cannabinoid prodrugs, and cannabinoid analogs, as well as novel cannabinoid prodrugs and cannabinoid analogs and treatment therapies."
Teewinot is scaling-up its proprietary processes in collaboration with Albany Molecular Research, Inc., a leading U.S. Contract Research Organization (CRO). With federally licensed laboratories in Canada, an Irish subsidiary, and global headquarters in Tampa, Florida, Teewinot is well-positioned to be a worldwide leader in the manufacturing and delivery of cannabinoid-based therapies.
About Teewinot Life Sciences Corporation
Teewinot Life Sciences Corporation is an international biopharmaceutical company focused on the use of novel biosynthetic processes such as biocatalysis and synthetic biology, as well as sophisticated formulation technologies, for the production and delivery of cannabinoid-based therapies. With headquarters in Tampa, Florida, Teewinot is an industry leader in the development and implementation of technologies for the cost-effective manufacture of pharmaceutically pure authentic cannabinoids. Teewinot's global technology and intellectual property portfolio represent a breakthrough in the manufacture and delivery of cannabinoid-based pharmaceuticals. For more information, please visit www.tlscorp.com or follow us on Twitter (@teewinot_corp).
For More Information:
Teewinot Life Sciences Corporation
SOURCE Teewinot Life Sciences Corporation